Patents by Inventor Eva-Maria Muchitsch

Eva-Maria Muchitsch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Subcutaneous administration of ADAMTS13
    Patent number: 11779635
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: October 10, 2023
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Alexandra Nathalie Kopic, Werner Hoellriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • SUBCUTANEOUS ADMINISTRATION OF ADAMTS13
    Publication number: 20220080032
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Application
    Filed: November 12, 2021
    Publication date: March 17, 2022
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Alexandra Nathalie KOPIC, Werner HOELLRIEGL, Barbara PLAIMAUER, Hanspeter ROTTENSTEINER, EVA-Maria MUCHITSCH
  • Subcutaneous administration of ADAMTS13
    Patent number: 11185575
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: November 30, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Alexandra Nathalie Kopic, Werner Hollriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • SUBCUTANEOUS ADMINISTRATION OF ADAMTS13
    Publication number: 20200101144
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Application
    Filed: September 11, 2019
    Publication date: April 2, 2020
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Alexandra Nathalie Kopic, Werner Hollriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • Subcutaneous administration of ADAMTS13
    Patent number: 10413600
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: September 17, 2019
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Alexandra Nathalie Kopic, Werner Höllriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • SUBCUTANEOUS ADMINISTRATION OF ADAMTS13
    Publication number: 20170224785
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Application
    Filed: February 22, 2017
    Publication date: August 10, 2017
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Alexandra Nathalie Kopic, Werner Höllriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • MODELS OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND METHODS OF USE THEREOF
    Publication number: 20170196994
    Abstract: The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.
    Type: Application
    Filed: January 24, 2017
    Publication date: July 13, 2017
    Applicants: BAXALTA INCORPORATED, BAXALTA GMBH
    Inventors: Hans-Peter Schwarz, Eva-Maria Muchitsch, Peter Turecek
  • Subcutaneous administration of ADAMTS13
    Patent number: 9611467
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 4, 2017
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Alexandra Nathalie Kopic, Werner Höllriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • Models of thrombotic thrombocytopenic purpura and methods of use thereof
    Patent number: 9587249
    Abstract: The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: March 7, 2017
    Assignees: BAXALTA GMBH, BAXALTA INCORPORATED
    Inventors: Hans-Peter Schwarz, Eva-Maria Muchitsch, Peter Turecek
  • SUBCUTANEOUS ADMINISTRATION OF ADAMTS13
    Publication number: 20140271611
    Abstract: This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein.
    Type: Application
    Filed: March 13, 2014
    Publication date: September 18, 2014
    Applicants: BAXTER HEALTHCARE SA, BAXTER INTERNATIONAL INC.
    Inventors: Alexandra Nathalie Schiviz, Werner Höllriegl, Barbara Plaimauer, Hanspeter Rottensteiner, Eva-Maria Muchitsch
  • Transgenic Mouse Lacking Endogenous FVIII and VWF - A Model of Hemophilia A
    Publication number: 20110072524
    Abstract: The present invention relates, generally, to a transgenic non-human animal model of hemophilia A, wherein the transgenic animal is deficient in endogenous Factor VIII and endogenous von Willebrand Factor, and methods to treat hereditary or acquired hemophilia A or von Willebrand Disease (VWD) by administration of exogenous human VWF.
    Type: Application
    Filed: August 4, 2010
    Publication date: March 24, 2011
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Peter Turecek, Raffi Udin Ahmad, Herbert Gritsch, Eva-Maria Muchitsch, Hans-Peter Schwarz
  • MODELS OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND METHODS OF USE THEREOF
    Publication number: 20100115637
    Abstract: The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.
    Type: Application
    Filed: October 27, 2009
    Publication date: May 6, 2010
    Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.
    Inventors: Hans-Peter Schwarz, Eva-Maria Muchitsch, Peter Turecek
  • Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
    Publication number: 20030069174
    Abstract: The invention relates to the use of human &agr;1-acid glycoprotein (AGP) for producing a pharmaceutical preparation for treating non-inflammatory disturbances of circulation or microcirculation, respectively.
    Type: Application
    Filed: November 19, 2002
    Publication date: April 10, 2003
    Inventors: Ludwig Pichler, Eva-Maria Muchitsch, Anton Philapitsch, Hans-Peter Schwarz, Yendra Linnau, Wolfgang Teschner